問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Far Eastern Memorial Hospital

Division of Thoracic Medicine

List

48Cases

2020-06-20 - 2027-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Not yet recruiting3Sites

Recruiting9Sites

Terminated1Sites

2015-02-25 - 2025-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting2Sites

Terminated10Sites

2015-08-01 - 2017-12-31

Phase III

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dupilumab in patients with persistent asthma

  • Condition/Disease

    persistent asthma

  • Test Drug

    dupilumab

Participate Sites
12Sites

Terminated10Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Cardiovascular Diseases

鍾啟禮
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Cardiovascular Diseases

2011-04-01 - 2012-11-16

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated7Sites

Study ended1Sites

2015-07-01 - 2015-12-12

Others

A 52-Week, Multicentre, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents with Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist (STRATOS 1)

  • Condition/Disease

    Asthma Inadequately Controlled

  • Test Drug

    Tralokinumab

Participate Sites
5Sites

Terminated3Sites

Study ended1Sites

2014-12-01 - 2018-12-31

Phase III

A randomised, double-blind, double dummy, chronic dosing (56 week) placebo-controlled, parallel group, multicentre, phase III study to evaluate the efficacy and safety of 3 doses of benralizumab (MEDI-563) in patients with moderateto very severe Chronic Obstructive Pulmonary Disease (COPD) with a history of COPD exacerbations (TERRANOVA)

  • Condition/Disease

    Chronic obstructive pulmonary disease

  • Test Drug

    Benralizumab

Participate Sites
8Sites

Terminated8Sites

2017-02-06 - 2018-12-31

IIT

Phase IV

The Protective Effect for Liver Organ in Patients With Anti-TB Drugs Using of Acteylcysteine (NAC)

  • Condition/Disease

    Tuberculosis

  • Test Drug

    Actein

Participate Sites
4Sites

Recruiting4Sites

2019-04-01 - 2022-05-31

Phase III

A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.

  • Condition/Disease

    idiopathic pulmonary fibrosis

  • Test Drug

    GLPG1690 (G451990)

Participate Sites
5Sites

Recruiting4Sites

許超群
Kaohsiung Municipal Gangshan Hospital

未分科

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2016-11-01 - 2019-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting8Sites

2020-08-07 - 2022-07-01

Phase II

A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection

  • Condition/Disease

    Severe Influenza Infection

  • Test Drug

    DAS181

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB